Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol -4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

作者：Davoren Jennifer E^*; Lee Che Wah; Garnsey Michelle; Brodney Michael A; Cordes Jason; Dlugolenski Keith; Edgerton Jeremy R; Harris Anthony R; Helal Christopher J; Jenkinson Stephen; Kauffman Gregory W; Kenakin Terrence P; Lazzaro John T; Lotarski Susan M; Mao Yuxia; Nason Deane M; Northcott Carrie; Nottebaum Lisa; O'Neil Steven V; Pettersen Betty; Popiolek Michael; Reinhart Veronica; Salomon Ferrer Romelia; Steyn Stefanus J; Webb Damien; Zhang Lei

来源：Journal of Medicinal Chemistry, 2016, 59(13): 6313-6328.

DOI：10.1021/acs.jmedchem.6b00544

It is hypothesized that selective muscarinic M-1 subtype activation could be a strategy to provide cognitive benefits to schizophrenia and Alzheimer's disease patients while minimizing the cholinergic side effects observed with nonselective muscarinic orthosteric agonists. Selective activation of M-1 with a positive allosteric modulator (PAM) has emerged as a new approach to achieve selective M-1 activation. This manuscript describes the development of a series of M-1-selective pyridone and pyridine amides and their key pharmacophores. Compound 38 (PF-06767832) is a high quality M-1 selective PAM that has well aligned physicochemical properties, good brain penetration and pharmacokinetic properties. Extensive safety profiling suggested that despite being devoid of mAChR M-2/M-3 subtype activity, compound 38 still carries gastrointestinal and cardiovascular side effects. These data provide strong evidence that M-1 activation contributes to the cholinergic liabilities that were previously attributed to activation of the M-2 and M-3 receptors.

• 出版日期2016-7-14